Literature DB >> 3057000

Clearing of epidermolysis bullosa acquisita with cyclosporine.

L L Crow1, J P Finkle, W R Gammon, D T Woodley.   

Abstract

Epidermolysis bullosa acquisita is a chronic, severe, subepidermal, blistering disease of the skin, characterized by marked resistance to topical and systemic therapy. This report concerns a well-documented case of a woman who had had epidermolysis bullosa acquisita for 6 years and had remained hospitalized continuously for 7 months in 1987. Her case ultimately was controlled with cyclosporine after the failure of a variety of therapeutic modalities in the hospital, including prednisone, methotrexate, azathioprine, phenytoin, vitamin E, gold sodium thiomalate (Myochrysine), isotretinoin, and plasmapheresis. In contrast to patients with pemphigus and pemphigoid treated with cyclosporine, our patient's autoantibodies did not disappear on therapy. Although its mechanism of action in epidermolysis bullosa acquisita is unknown, we propose that cyclosporine may be a helpful drug for patients whose disease is refractory to more traditional forms of therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3057000     DOI: 10.1016/s0190-9622(88)70254-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

1.  [Mucosal epidermolysis bullosa acquisita complicated by laryngeal stenosis].

Authors:  S Ritzmann; W Angerstein; N J Neumann; M Megahed
Journal:  Hautarzt       Date:  2004-10       Impact factor: 0.751

Review 2.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 3.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Epidermolysis bullosa acquisita--successful treatment with colchicine.

Authors:  M Megahed; K Scharffetter-Kochanek
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

Review 6.  Autoimmunity to type VII collagen: epidermolysis bullosa acquisita.

Authors:  David T Woodley; Jennifer Remington; Mei Chen
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

7.  Therapy of autoimmune bullous diseases.

Authors:  Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

Review 8.  Autoimmunity against type VII collagen in inflammatory bowel disease.

Authors:  Gheorghe Hundorfean; Markus F Neurath; Cassian Sitaru
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.